Clinuvel Pharmaceuticals Seeks to Uplist American Depositary Receipt Program on Nasdaq

MT Newswires Live

2025/12/19

Clinuvel Pharmaceuticals (ASX:CUV) filed a draft registration statement with the US Securities and Exchange Commission (SEC), seeking to uplist its American depositary receipt (ADR) program on the Nasdaq Stock Market to Level II from Level I, according to a Friday Australian bourse filing.

Around 25% of the firm's issued capital is currently held by US-based investors, the filing noted. If approved, its ADR is expected to trade on Nasdaq with the ticker "CLVL."

The submission of the draft registration statement, including the Form 20-F annual report, is necessary for the SEC to recognize a non-US company as a "Foreign Private Issuer" and list securities on US stock exchanges. After the initial filing, the SEC will review the registration statement and provide feedback within a 30-day window.

Its shares rose over 2% in recent trading on Friday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2592135240"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592135240\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592135240?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 09:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592135240","market":"nz","top_or_hot":-1,"title":"Clinuvel Pharmaceuticals Seeks to Uplist American Depositary Receipt Program on Nasdaq","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> (ASX:CUV) filed a draft registration statement with the US Securities and Exchange Commission (SEC), seeking to uplist its American depositary receipt (ADR) program on the Nasdaq Stock Market to Level II from Level I, according to a Friday Australian bourse filing.</p><p>Around 25% of the firm's issued capital is currently held by US-based investors, the filing noted. If approved, its ADR is expected to trade on Nasdaq with the ticker \"CLVL.\"</p><p>The submission of the draft registration statement, including the Form 20-F annual report, is necessary for the SEC to recognize a non-US company as a \"Foreign Private Issuer\" and list securities on US stock exchanges. After the initial filing, the SEC will review the registration statement and provide feedback within a 30-day window.</p><p>Its shares rose over 2% in recent trading on Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinuvel Pharmaceuticals Seeks to Uplist American Depositary Receipt Program on Nasdaq</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinuvel Pharmaceuticals Seeks to Uplist American Depositary Receipt Program on Nasdaq\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-19 09:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> (ASX:CUV) filed a draft registration statement with the US Securities and Exchange Commission (SEC), seeking to uplist its American depositary receipt (ADR) program on the Nasdaq Stock Market to Level II from Level I, according to a Friday Australian bourse filing.</p><p>Around 25% of the firm's issued capital is currently held by US-based investors, the filing noted. If approved, its ADR is expected to trade on Nasdaq with the ticker \"CLVL.\"</p><p>The submission of the draft registration statement, including the Form 20-F annual report, is necessary for the SEC to recognize a non-US company as a \"Foreign Private Issuer\" and list securities on US stock exchanges. After the initial filing, the SEC will review the registration statement and provide feedback within a 30-day window.</p><p>Its shares rose over 2% in recent trading on Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2592135240","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592135240","pubTimestamp":1766107403,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clinuvel Pharmaceuticals  filed a draft registration statement with the US Securities and Exchange Commission , seeking to uplist its American depositary receipt  program on the Nasdaq Stock Market to Level II from Level I, according to a Friday Australian bourse filing.Around 25% of the firm's issued capital is currently held by US-based investors, the filing noted. If approved, its ADR is expected to trade on Nasdaq with the ticker \"CLVL.\"The submission of the draft registration statement, including the Form 20-F annual report, is necessary for the SEC to recognize a non-US company as a \"Foreign Private Issuer\" and list securities on US stock exchanges. After the initial filing, the SEC will review the registration statement and provide feedback within a 30-day window.Its shares rose over 2% in recent trading on Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7094":"医疗保健技术","SEC.AU":"SPHERIA EMERGING CO LTD","ADR.AU":"Adherium Ltd","BK4107":"财产与意外伤害保险","BK4117":"多元化保险","CUV.AU":"CLINUVEL PHARMACEUTICALS LTD","BK7067":"生物科技","AFG":"美国金融集团有限公司"},"translate_title":"Clinuvel Pharmaceuticals寻求在纳斯达克上市美国存托凭证计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADR.AU":1,"AFG":1.5,"CUV.AU":1,"NQmain":1.5,"SEC.AU":1},"content_text":"Clinuvel Pharmaceuticals (ASX:CUV) filed a draft registration statement with the US Securities and Exchange Commission (SEC), seeking to uplist its American depositary receipt (ADR) program on the Nasdaq Stock Market to Level II from Level I, according to a Friday Australian bourse filing.Around 25% of the firm's issued capital is currently held by US-based investors, the filing noted. If approved, its ADR is expected to trade on Nasdaq with the ticker \"CLVL.\"The submission of the draft registration statement, including the Form 20-F annual report, is necessary for the SEC to recognize a non-US company as a \"Foreign Private Issuer\" and list securities on US stock exchanges. After the initial filing, the SEC will review the registration statement and provide feedback within a 30-day window.Its shares rose over 2% in recent trading on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}